written on 13.03.2014

Another Glaxo respiratory drug sees regulatory filings in its future


The British pharma giant says it's nailed the primary endpoint in a Phase III study of its injectable candidate mepolizumab, which will help set the severe eosinophilic asthma treatment up for its first regulatory filings.

Latest Reports